Cited by 852Diabetes Treatment and ManagementDiabetes Management and ResearchDiabetes Management and Education

The DOI matches its Crossref record; 112 of the 114 references it cites were found in a registry or an index.

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023

Open access

ElSayed, Nuha A., Aleppo, Grazia, Aroda, Vanita R., Bannuru, Raveendhara R., Brown, Florence M., Bruemmer, Dennis, Collins, Billy S., Hilliard, Marisa E., Isaacs, Diana, Johnson, Eric L., Kahan, Scott, Khunti, Kamlesh, Leon, Jose, Lyons, Sarah K., Perry, Mary Lou, Prahalad, Priya, Pratley, Richard E., Seley, Jane Jeffrie, Stanton, Robert C., Gabbay, Robert A.·2023·Diabetes Care

DOI 10.2337/dc23-s009PMC PMC9810476

Open this paper in CoChat — free account Open PDF

Abstract

The American Diabetes Association (ADA) “Standards of Care in Diabetes” includes the ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee, a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA’s clinical practice recommendations and a full list of Professional Practice Committee members, please refer to Introduction and Methodology. Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.2337/dc23-s009

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the american diabetes association (ADA) and the european association for the study of diabetes (EASD)
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Self-citation
Untitled work
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D’Alessio, D. A., & Davies, M. J. (2020) · Diabetes Care · doi:10.2337/dci19-0066 · Cited by 1,192
Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association
Chiang, J. L., Kirkman, M. S., Laffel, L. M., Peters, A. L., & Authors, O. B. O. T. T. 1. D. S. (2014) · Diabetes Care · doi:10.2337/dc14-1140 · Cited by 1,039
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829
Self-citation

Flagged first, then by citations

Show all 114 references

2 of the 114 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

Peters, 2013, American Diabetes Association/JDRF Type 1 Diabetes Sourcebook

Sorted by citations

Items 501–600 of 852

Expert Consensus on Dipeptidyl Peptidase-4 Inhibitor-Based Therapies in the Modern Era of Type 2 Diabetes Mellitus Management in India
Kalra, S., Bhattacharya, S., Dhingra, A., Das, S., Kapoor, N., Shaikh, S. S., Kolapkar, V., Kumar, R. V. L., Patel, K., & Kotwal, R. (2024) · Cureus · doi:10.7759/cureus.61766 · Cited by 5
Comparation of fixed‐ratio (IDegLira and iGlarLixi) versus free combination of basal insulin and glucagon‐like peptide‐1 receptor agonist for uncontrolled type 2 diabetes: A systematic review and network meta‐analysis
Weng, J., Tao, Y., Xu, Z., Zhou, S., Xiao, D., Zhu, Z., Zheng, R., Yang, Y., & Chen, Y. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12620 · Cited by 3
Association between low cognitive performance and diabetes‐related health indicators across racial and ethnic groups in adults with diabetes
Li, P., Alkhuzam, K. A., Brown, J. D., Zhang, Y., Jiao, T., Guo, J. S., Umpierrez, G. E., Narayan, K. M. V., Kulshreshtha, A., Pasquel, F. J., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15715 · Cited by 3
Comparison of Nurse Practitioner and Physician Management of Diabetes in Japan
Shozuhara, T., & Suzuki, M. (2024) · The Journal for Nurse Practitioners · doi:10.1016/j.nurpra.2024.105130 · Cited by 3
Time‐in‐range derived from self‐measured blood glucose in people with type 2 diabetes advancing to iGlarLixi : A participant‐level pooled analysis of three phase 3 LixiLan randomized controlled trials
Haluzı́k, M., Al‐Sofiani, M. E., CHENG, A. Y. Y., Lauand, F., Melas‐Melt, L., & Rosenstock, J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15811 · Cited by 3
Comparing ischemic cardiovascular effectiveness and safety between individual SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes: a nationwide population-based cohort study
Kim, H., Seo, J., Nam, J. H., Lim, Y., Choi, K. H., & Kim, K. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1443175 · Cited by 3
TO MARKET, TO MARKET—2023: SMALL MOLECULES
Araujo, E., Bartels, B., Bell, I. M., Castanedo, G. M., Zeng, M., Dhar, T. G. M., Holmberg‐Douglas, N., Welin, E. R., Koester, D. C., León, B., et al. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch19 · Cited by 3
Emirates consensus recommendations on cardiovascular risk management in type 2 diabetes
Sabbour, H. M., Almahmeed, W. A., Alawadi, F., Shehab, A. M., Zubaidi, A. A., Bashier, A. M., Ghulam, A. R., Rashid, F., Zaky, H., Kassem, H. H., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1395630 · Cited by 3
Relieved Depressive State and Glycemic Control in Type 2 Diabetes (T2D) Patient Treated by Imeglimin (Twymeeg)
Okada, M., Bando, H., Iwatsuki, N., Sakamoto, K., & Ogawa, T. (2023) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2023/asjbccr.6303 · Cited by 3
Actual Meal of Low Carbohydrate Diet (LCD) for Diabetic Patient Treated by Effective Imeglimin (Twymeeg)
Kusumoto, T., Bando, H., Hayashi, K., Yasuoka, E., Shibata, M., & Takagishi, H. (2023) · Asploro Journal of Biomedical and Clinical Case Reports · doi:10.36502/2023/asjbccr.6312 · Cited by 3
Effect of Human Adenovirus 36 on Response to Metformin Monotherapy in Obese Mexican Patients with Type 2 Diabetes: A Prospective Cohort Study
Tapia-Rivera, J. C., Mendoza-Jaramillo, H. E., González-Villaseñor, C. O., Ramírez-Flores, M., Aguilar‐Velázquez, J. A., López-Quintero, A., Pérez-Guerrero, E. E., Vargas-Rodriguez, M. D. L. Á., Gutiérrez-Hurtado, I. A., & Martínez‐López, E. (2023) · Viruses · doi:10.3390/v15071514 · Cited by 3
National Changes in Diabetes Care Practices during the COVID-19 Pandemic: Prospective Study of US AdultsPreprint
Vashist, K., Hassan, S., Weber, M. B., Quarells, R. C., & Patel, S. A. (2023) · medRxiv · doi:10.1101/2023.08.06.23293722 · Cited by 3
The “pandemic” increase of GLP-1 receptor agonists use and the time of discontinuation before anesthesia: Something new?
Vetrugno, L., D’Ardes, D., & Deana, C. (2024) · Journal of Clinical Anesthesia · doi:10.1016/j.jclinane.2024.111693 · Cited by 3
Persistence of Weekly Injectable Semaglutide Use in Patients with Diabetes Mellitus and Obesity: A Retrospective Follow-Up in Colombia
Machado-Duque, M. E., Gaviria-Mendoza, A., Valladales-Restrepo, L. F., & Machado-Alba, J. E. (2025) · Drugs - Real World Outcomes · doi:10.1007/s40801-025-00518-6 · Cited by 2
Evolución clínica de los pacientes con FA y diabetes mellitus en la pandemia de COVID-19. Registro REFADI
Barón‐Esquivias, G., Ruiz, I. E., Gómez-Moreno, S., Hidalgo, I. S., Gómez-Barrado, J. J., Martín-Santana, A. M., Sánchez-Brotons, J. A., Romero-Garrido, R., & Fernández-Romero, A. (2023) · REC CardioClinics · doi:10.1016/j.rccl.2023.04.006 · Cited by 2
Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus
Duong, A., Heacock, S., Amering, S., Brennan, L., Venci, J. V., & Acquisto, N. M. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231199852 · Cited by 2
Factors Correlated to the Renoprotective Effect of Sitagliptin in Patients with Type 2 Diabetes Mellitus: Retrospective Observational Study
Khunkit, P., & Wattana, K. (2024) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/2024/7181515 · Cited by 2
Cardiovascular and renal benefits of sodium-glucose cotransporter-2 inhibitors: pathophysiologic mechanisms and clinical evidence
Small, A. M., & Wiviott, S. D. (2024) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.24.06600-6 · Cited by 2
Therapeutic tailored approach in patients with diabetes, cardiovascular and renal comorbidities: A cardiologist's view
Nardi, E., Prastaro, M., Santoro, C., Gallo, L., Simeoli, L., Fontanarosa, S., Paolillo, S., Gargiulo, P., Esposito, G., & Filardi, P. P. (2025) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2025.104033 · Cited by 3
The contemporary landscape of cardiovascular optimization in type 2 diabetes: overcoming barriers to evidence-based use of newer antihyperglycemic agents
Malas, K., Kazmi, S., Kang, Y. M., & McGuire, D. K. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2504702 · Cited by 3
Effect of initial combination therapy vs. step-therapy on adherence and persistence in drug naïve type 2 diabetes patients
Majd, Z., Chen, H., Johnson, M. L., Birtcher, K. K., Serna, O., Fatima, B., & Abughosh, S. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109080 · Cited by 2
Optimized layered microneedle design for precise transdermal drug delivery: Overcoming skin elasticity Challenges
Ling, Y., He, Y., Su, N., Chen, N., Yang, M. W. O., Liu, R., Chen, B. Z., & Guo, X. D. (2025) · Journal of Industrial and Engineering Chemistry · doi:10.1016/j.jiec.2025.05.021 · Cited by 2
Mathematical Modeling in Diabetes Care and Innovation
Maamar, M. H. (2025) · Industrial and applied mathematics · doi:10.1007/978-981-96-1925-2_4 · Cited by 2
Assessment of Large Language Models for Enhancing Diabetologist-Developed Personalized Treatment Plans in Complex Type 2 Diabetes
Wang, M., Sushil, M., Williams, C. Y. K., Miao, B. Y., Kim, S., Masharani, U. B., Ku, G., Hsiao, V. C., Shah, A., Koliwad, S. K., et al. (2025) · Clinical Diabetes · doi:10.2337/cd25-0015 · Cited by 3
A review of the effect of SGLT2 inhibitors on clinical and glycemic outcomes in hospitalized patients: data from studies that included patients with diabetes
Ntelis, S., Singh, L. G., Hernandez, R., & Spanakis, E. K. (2025) · HORMONES · doi:10.1007/s42000-025-00702-x · Cited by 3
Multiple analysis based on dual-mode anion-exchange chromatography strategy reveals significant impact of charge heterogeneity on structure and function of dulaglutide
Gong, F., Shen, Z., Sun, B., Deng, L., Han, L., Xu, H., & Dou, C. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.147808 · Cited by 2
A study on the clinical effectiveness of a tiered management model for type 2 diabetes based on a three-level linkage mechanism in the context of residency training: a randomized controlled trial
Wu, S., Liu, T., Chen, L., Wang, M., Deng, J., & Yang, Q. Z. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1618181 · Cited by 2
Effects of insulin regimens for type 2 diabetes mellitus: a systematic review and network meta-analysis
Bertuol, V. C., Iorra, F. D. Q., Vieceli, T., Tonolli, N. T., Zappelini, R. D. S., van der Sand, L. F., Leitão, C. B., & Rados, D. R. V. (2025) · Diabetologia · doi:10.1007/s00125-025-06633-x · Cited by 3
Fuc‐S, a New Degraded Polysaccharide From Fucoidan, Alleviates Type 2 Diabetes‐Associated Liver Injury Through Modulating Gut Microbiota
Du, B., Cheng, C., Feng, J., Liang, Y., Tao, W., Xu, B., Peng, J., Zhang, G., & Yang, Y. (2026) · Food Science & Nutrition · doi:10.1002/fsn3.71321 · Cited by 2
Explainable deep learning framework incorporating medical knowledge for insulin titration in diabetes
He, H., Ying, Z., Li, B., Fan, Y., Wang, P., Lu, J., Wu, L., Zhao, H., Guo, Y., Wang, G., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01449-1 · Cited by 2
Development of a liver stiffness measurement-based nomogram model to identify early CKD risk in patients with MAFLD
Huang, D., Ma, X., Gao, Q., Shen, X., Yu, T., & Wang, R. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04701-z · Cited by 2
A Systematic Review and Meta-Analysis of Efficacy and Safety of Liraglutide in Patients with Type 2 Diabetes Mellitus
Joshi, S., Das, A. K., Khunti, K., Khunti, S., & CHOUDHARI, S. Y. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s570273 · Cited by 3
Self-citation
Optimal lifelong roadmap post-acute coronary syndrome: a clinical consensus statement of the European Association of Preventive Cardiology of the European Society of Cardiology
Pedretti, R. F. E., Craenenbroeck, E. M. V., Vrints, C., Ambrosetti, M., Kurpas, D., Vassiliou, V. S., Bäck, M., Moholdt, T. T., Sionís, A., Wilhelm, M., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag236 · Cited by 6
Circadian rhythms in cardiovascular disease: a new perspective on inter-organ crosstalk
Liu, L., Cai, Y., Zhu, M., Liu, Y., & Liu, Y. (2026) · Medicine Plus · doi:10.1016/j.medp.2026.100140 · Cited by 2
GLP-1 receptor agonist–SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes
Mao, X., Fan, H., Yuen, M.-F., Cheung, R. C., Seto, W., & Nguyen, M. H. (2026) · Hepatology · doi:10.1097/hep.0000000000001771 · Cited by 3
Living with Type 2 Diabetes: Podcast of a Patient–Physician Discussion
Kushner, P. R., & Dalin, A. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01378-5 · Cited by 2
Advancing therapy in people with suboptimally controlled basal insulin‐treated type 2 diabetes: Subanalysis of the SoliMix trial in participants in Latin American countries
Frechtel, G. D., Sauque‐Reyna, L., Choza‐Romero, R., Anguiano, L., Melas‐Melt, L., & Sañudo‐Maury, M. E. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15125 · Cited by 2
Use of Cardioprotective Antidiabetic Medications in Adults With and Without Cardiovascular Disease, 2015 to March 2020
Sherrill, C. H., & Hwang, A. Y. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231178886 · Cited by 2
Minimization of drug interactions in polypharmacy treatments of diabetes mellitus type 2 with cardiovascular comorbidities by using the decision support tool PM-TOM
Kulenović, A., & Lagumdzija-Kulenovic, A. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101267 · Cited by 2
Use of Diabetes Medications before and after a Heart Failure–Related Hospitalization among Nursing Home Residents
Zhang, T., Zullo, A. R., Hayes, K. N., Kim, D. H., Lee, Y., Daiello, L. A., Kiel, D. P., & Berry, S. D. (2023) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2023.06.033 · Cited by 2
Optimizing Type 2 Diabetes Management in a Medically Complex Patient: A Case Report of a Patient with Type 2 Diabetes and HIV
Kabakambira, J. D., & Kong, J. M. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s415949 · Cited by 2
Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up
Grigorescu, E.-D., Lăcătușu, C.-M., Floria, M., Cazac, G.-D., Onofriescu, A., Sauciuc, L. A., Ceasovschih, A., Crețu, I., Mihai, B. M., & Șorodoc, L. (2023) · Diagnostics · doi:10.3390/diagnostics13172817 · Cited by 2
Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study
Hoog, M. M., Paczkowski, R., Huang, A., Halpern, R., Buysman, E. K., Stackland, S., Zhang, Y., & Dixon, R. W. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01473-7 · Cited by 2
Type 2 Diabetes-Etiology, Epidemiology, Pathogenesis, Treatment
Burns, C., & Francis, N. (2023) · Springer eBooks · doi:10.1007/978-3-319-12125-3_34-3 · Cited by 2
The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled Trials
Ghosal, S., Ghosal, S., & Ghosal, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206462 · Cited by 2
Comparison of the efficacy of anti-diabetic medications as add-on to metformin in type 2 diabetes mellitus from a real-world database
Ono, R., Ogami, C., Hasegawa, C., To, H., Matsumoto, Y., & Tsuji, Y. (2023) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-023-00716-4 · Cited by 4
Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials
Munshi, M. N., Ritzel, R. A., Jude, E. B., DEX, T. A., Melas‐Melt, L., & Rosenstock, J. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15377 · Cited by 2
Stroke Prevention by Antihyperglycemic Drugs in Type 2 Diabetes Mellitus
Albert, S. G., Shrestha, E., & Ahir, V. (2023) · Endocrine Practice · doi:10.1016/j.eprac.2023.12.007 · Cited by 2
Liraglutide and Robust A1C Reductions Among People With Type 2 Diabetes Requiring Appetite Control: A Review of Two Cases
Pitts, M. A., Griggs, R. H., Hall, M., Tankersley, M., & Johnson, J. L. (2023) · Diabetes Spectrum · doi:10.2337/ds23-0052 · Cited by 2
Treatment Approaches and Challenges
Malboosbaf, R., & Hatami, N. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815196535123010005 · Cited by 2
An estimate of the need for continuous glucose monitoring in type 2 diabetes with intensive insulin treatment in secondary healthcare
Trolle, C., Christensen, M., & Hansen, K. W. (2024) · Diabetic Medicine · doi:10.1111/dme.15298 · Cited by 2
Role of Chia Seed (Salvia hispanica L.) Supplements in Managing Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis
Kamrul-Hasan, A. B. M., Yadav, A., Mondal, E., Nepali, R. B., Nur-A-Musabber, & Aalpona, F. T. Z. (2024) · Bangladesh Journal of Endocrinology and Metabolism · doi:10.4103/bjem.bjem_1_24 · Cited by 2
Factors associated with an increased risk of vitamin B12 deficiency in patients with type 2 diabetes mellitus on metformin
Wagner, R., Mahashabde, R. V., Painter, J. T., & Boehmer, K. (2024) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1913 · Cited by 2
Consistent glycaemic efficacy and safety of concomitant use of iGlarLixi and sodium-glucose co-transporter-2 inhibitor therapy for type 2 diabetes: A patient-level pooled analysis of three randomised clinical trials
Giorgino, F., Guja, C., Aydın, H., Lauand, F., Melas‐Melt, L., & Rosenstock, J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111604 · Cited by 2
Evaluation of Efficacy and Safety of Empagliflozin in Bangladeshi Patients with Type 2 Diabetes Mellitus (EFFISAEM Study)
Saifuddin, M., Paul, A., Shefin, S. M., Alam, M. J., Selim, S., Islam, S., Hossain, T., Tuqan, S., Sultana, N., Mustari, M., et al. (2024) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_189_23 · Cited by 2
Opportunities to overcome underutilization of enhanced insulin delivery technologies in people with type 2 diabetes: a narrative review
Kruger, D. F., Isaacs, D. M., Hughes, L., Miller, E. M., & Bailey, T. S. (2024) · Postgraduate Medicine · doi:10.1080/00325481.2024.2331417 · Cited by 2
Self-citation
Ianus Bifrons: The Two Faces of Metformin
Goglia, U., Hasballa, I., Teti, C., Boschetti, M., Ferone, D., & Albertelli, M. (2024) · Cancers · doi:10.3390/cancers16071287 · Cited by 2
Perceptions and Experiences of People with Obesity and Type 2 Diabetes Around Appetite and Eating Behaviors: A Qualitative Study
Poon, J. L., O’Hara, L., Kendal, H., Sully, K., Guy, M., Bradley, H., Tolley, C., & Mason, B. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02846-5 · Cited by 3
Comparing the Effect of Early Versus Delayed Metformin Treatment on Glycaemic Parameters Among Australian Adults With Incident Diabetes: Evidence Using a National General Practice Database
Zheng, M., Begum, M., Bernardo, C., Stocks, N. P., & González‐Chica, D. A. (2024) · Clinical Therapeutics · doi:10.1016/j.clinthera.2024.03.001 · Cited by 3
Prandial Insulins: A Person-Centered Choice
Attri, B., Nagendra, L., Dutta, D., Shetty, S., Shaikh, S. S., Kalra, S., & Bhattacharya, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01540-8 · Cited by 2
Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL
Gooding, K. M., Stevens, S. R., Lokhnygina, Y. V., Giczewska, A., Shore, A. C., & Holman, R. R. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111685 · Cited by 2
A Case Report of Bardet Biedl Syndrome in a Patient from Pakistan who Presented with Osmotic Symptoms associated with Diabetes Mellitus
Babar, B., Shaukat, M. A., Manzoor, M., Bibi, S., & Khan, H. (2024) · International Journal of Medical Students · doi:10.5195/ijms.2024.1932 · Cited by 2
Inibidores de SGLT2 e inflamassoma NLRP3: alvo potencial na doença renal do diabetes
Júnior, P. A. B. M., Lass, A. D., Pilger, B. I., Fornazari, R., de Moraes, T. P., & Pinho, R. A. (2024) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2023-0187pt · Cited by 2
Improved Clinical Outcomes with the Combination Therapy of a Glucagon-like Peptide-1 Receptor Agonists and a Sodium-glucose Cotransporter-2 Inhibitor in Overweight/Obese People with Type 2 Diabetes: Real-world Evidence from the Indian Subcontinent
Nigam, A. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0644 · Cited by 2
Sirtuin Expression in Insulin-Sensitive Tissues of Rats with Impaired Glucose Tolerance is not Affected by Resistance Training or Zinc Supplementation
García‐Díaz, D. F., Pérez, A., Barham, A., Cano-Cappellacci, M. A., Vásquez, K., Pérez‐Bravo, F., Inostroza, J., Codoceo, J., Orellana, J., Samman, S., et al. (2024) · Biological Trace Element Research · doi:10.1007/s12011-024-04397-w · Cited by 2
The Michigan Collaborative for Type 2 Diabetes (MCT2D): Development and implementation of a statewide collaborative quality initiative
Oshman, L. D., Bhomia, N., Diez, H. L., Gabison, J. G., Gorin, S. S., Hafez, D., Hisamatsu, R., Heung, M., Jamison, C. D., KHOSROVANEH, K. L., et al. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-11520-z · Cited by 2
Assessing 1-year sodium-glucose co-transporter-2 inhibitor tolerance in older adults
Schäfer, S., Zeithamel, M. C., Waterbury, N. V., & Lund, B. C. (2024) · Age and Ageing · doi:10.1093/ageing/afae237 · Cited by 2
Bridging the Gap Between Diabetes and Cardiovascular Disease: A Comparative Review of Different Glucagon-Like Peptide-1 (GLP-1) Agonists: Efficacy, Safety, and Patient Outcomes
Alghamdi, F. A., Alshegifi, H., Alhuthayli, R., Helal, T., Huwait, T. A., Alharbi, T., Akbar, A. F., Alshehri, W., & Alsheikh, S. (2024) · Cureus · doi:10.7759/cureus.74345 · Cited by 3
Efficacy of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists on proteinuria and weight in a diabetes cohort
Lu, D., Zheng, R., Li, A., & Zhang, J. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.98552 · Cited by 2
Effectiveness and safety of iGlarLixi in people with type 2 diabetes not at target on basal insulin and oral antidiabetic therapy in a prospective observational trial
Seufert, J., Wiesner, T., Pegelow, K., Kenzler, J., & Pfohl, M. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16161 · Cited by 3
Nanostructure-Based Drug Delivery in Alleviating Type 2 Diabetes Mellitus
Saini, A., Nagar, L., Panwar, R., Pahwa, R., Dua, K., Dureja, H., & Verma, P. K. (2025) · BioNanoScience · doi:10.1007/s12668-024-01786-2 · Cited by 2
Comparative effectiveness of insulin glargine, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose cotransporter‐2 inhibitors in veterans with type 2 diabetes
Shen, J., Sarwal, A., Singh, R., Hartsell, S. E., Wei, G., Nevers, M. R., Christensen, J. C., Takyi, A., Katkam, N., Derington, C. G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16207 · Cited by 3
A Randomized Phase 3 Study Evaluating the Efficacy and Safety of Alogliptin in Pediatric Participants with Type 2 Diabetes Mellitus
Peng, X., KLINGENSMITH, G. J., Hsia, D. S., Xie, Y., Czerniak, R., Tamborlane, W. V., & SHAH, A. S. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01700-3 · Cited by 2
Evidence-based pharmacological investigation of the clinical practice and rational use of metformin in prediabetes mellitus
Liu, D., Chen, X., Wang, Q., Pan, X., Wei, X., Wang, B., Wang, Y., Xue, X., & Lu, C. (2025) · Precision medication. · doi:10.1016/j.prmedi.2025.100035 · Cited by 2
Quality of antidiabetic medicines in 13 sub-Saharan African countries: a cross-sectional survey
Antignac, M., N’Guetta, R., Secrétan, P.-H., Do, B., Ikama, M. S., Mipinda, J. B., Toure, I. A., Takombe, J. L., Lubenga, Y. N., Dia, M. M., et al. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103405 · Cited by 2
Mitos y creencias sobre la insulinoterapia en pacientes con diabetes mellitus y sus familiares de un hospital del norte del Perú, 2020
Ubillús, J. L. V., Loayza-Enriquez, B. K., Lozano, R. E. G., & León-Jiménez, F. (2023) · Revista Peruana de Medicina Experimental y Salud Pública · doi:10.17843/rpmesp.2023.401.12210 · Cited by 2
Descriptive study of a clinical and educational telemedicineintervention in patients with diabetes receiving glargine 300U/ml (Toujeo) in Spain: results of the T-Coach programme
Bellido, V., Morales, C., Muñoz‐Garach, A., Almeida, J. M. G., Fernández-Morera, J. L., Aguilera, B. G., de la Torre, M. L., & Bellido, D. (2023) · Drugs in Context · doi:10.7573/dic.2023-1-1 · Cited by 1
Anemia combined with albuminuria increases the risk of cardiovascular and renal events, regardless of a reduced glomerular filtration rate, in patients with type 2 diabetes: a prospective observational study
Ito, H., Matsumoto, S., Inoue, H., Izutsu, T., Kusano, E., Antoku, S., Yamasaki, T., Mori, T., & Togane, M. (2023) · Diabetology International · doi:10.1007/s13340-023-00637-x · Cited by 2
Unusual case of concurrent metformin-associated lactic acidosis and euglycaemic ketoacidosis
Koo, G. P. Y., Dutta, A., & Zhang, Y. H. (2023) · Proceedings of Singapore Healthcare · doi:10.1177/20101058231204703 · Cited by 2
Outcomes and Attributes Patients Value When Choosing Glucose-Lowering Medications: A Mixed-Methods Study
Golembiewski, E. H., Bautista, A. E. G., Polley, E. C., Umpierrez, G. E., Galindo, R. J., Brito, J. P., Montori, V. M., Gockerman, J. P., Tesulov, M., Labatte, B., et al. (2024) · Clinical Diabetes · doi:10.2337/cd23-0042 · Cited by 2
Effectiveness of Oral Semaglutide in Weight Loss and Glycemic Control among Type 2 Diabetes Population: A Real-world Longitudinal Study
Kesavadev, J., Ashik, A., Yasmin, S., Raj, K. S., Krishnan, G., Basanth, A., & Shankar, A. (2023) · International Journal of Diabetes and Technology · doi:10.4103/ijdt.ijdt_33_23 · Cited by 3
Care of Diabetes and the Sacrifice of Evidence-Based Medicine and Health Equity
Goldberg, D. N. (2024) · Journal of General Internal Medicine · doi:10.1007/s11606-024-08907-3 · Cited by 2
Metformin impairs trophoblast metabolism and differentiation in dose dependent mannerPreprint
Nashif, S. K., Mahr, R. M., Jena, S., Jo, S., Nelson, A. B., Sadowski, D., Crawford, P. A., Puchalska, P., Alejandro, E. U., Gearhart, M. D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.14.528531 · Cited by 2
SGLT-2 Inhibitors: Discrepancy Between MACE Reduction and Incident MI and Stroke
Broome, D. T. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad216 · Cited by 2
Insulin Management in Patients With Diabetes Receiving Hemodialysis: Unanswered Questions and Way Forward
McCoy, R. G., & O’Connor, P. J. (2023) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2023.10.001 · Cited by 2
The efficacy of switching basal–bolus insulin therapy to basal insulin-supported oral therapy with a glinide and an α-glucosidase inhibitor in patients with type 2 diabetes depends on insulin secretory capacity, but not on blood glucose profiles and insulin dosages prior to the switching
Ando, T., Kondo, M., Asada‐Yamada, Y., Kawai, M., Asano‐Hayami, E., Hayami, T., Motegi, M., Ejima, Y., Nagao, E., Kasagi, R., et al. (2023) · Diabetology International · doi:10.1007/s13340-023-00651-z · Cited by 1
Hypoglycemia
Beattie, S. (2023) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000100 · Cited by 1
The Principles of Insulin Management of Type 2 Diabetes Mellitus
Kawa, L. B., & Alexander, H. (2023) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2023.134022 · Cited by 1
Impact of Liraglutide to Semaglutide Conversion on Glycemic Control and Cost Savings at a Veterans Affairs Medical Center
Hardin, M. (2023) · Federal Practitioner · doi:10.12788/fp.0413 · Cited by 1
Persistence to Basal Insulin: Association With Health Outcomes in a Population With Type 2 Diabetes
Nsiah, I., Campbell, P. J., Parikh, M. A., Hines, L. E., Pickering, M. K., & Nau, D. P. (2023) · Clinical Diabetes · doi:10.2337/cd23-0016 · Cited by 1
The Effect of Metabolic Control on Diabetes Complication Rates and the Need for Medical Care During COVID-19 Social Isolation in Adjara, Georgia
Jashi, L., Kvanchakhadze, R., Peshkova, T., Dundua, K., Nakaidze, L., Margalitadze, E., & Gachechiladze, T. (2023) · Cureus · doi:10.7759/cureus.51093 · Cited by 1
Using insulin pump for glycemic control in patients with severe insulin resistance
Procaccini, M., Allegra, A. G., Burns, D., & Sisson, E. M. (2024) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2024.01.003 · Cited by 1
Factors and economic burden of non-severe hypoglycemia among insulin-treated type 2 diabetes patients: a cross-sectional study
Kosachunhanun, N., Wongsa, D., & Permsuwan, U. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2312160 · Cited by 1
β-Cell Function, Incretin Effect, and Glucose Kinetics in Response to a Mixed Meal in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin
Daniele, G., Tura, A., Brocchi, A., Saba, A., Campi, B., Sancho‐Bornez, V., Dardano, A., & Prato, S. D. (2024) · Diabetes Care · doi:10.2337/dc23-2051 · Cited by 1
Characterization of tirzepatide‐treated patients achieving different glycemic control levels in SURPASS‐AP‐Combo
Bao, Y., Han, L., Du, L., & Ji, L. (2024) · Obesity · doi:10.1002/oby.24030 · Cited by 1
Effectiveness and safety of once-weekly semaglutide: findings from the SEMACOL-REAL retrospective multicentric observational study in Colombia
Buenaventura, D. C., Ramos, A. F. G., Valencia, C. M. B., Aguilar-Londoño, C., Coronel-Restrepo, N., Monsalve, C., Cuesta, D., & Rincón, A. R. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1372992 · Cited by 1
Epidemiological profile of patients with type 2 diabetes mellitus treated at a teaching-assistance unit in Northeast Brazil
Sales, A. M. S., Ferreira, J. G., Vasco, R. F. V., & Albuquerque, E. V. D. A. (2024) · HSJ. · doi:10.21876/hsjhci.v14.2024.e1500 · Cited by 1
Modeling Metformin and Dapagliflozin Pharmacokinetics in Chronic Kidney Disease
Shahidehpour, A., Rashid, M. M., Askari, M. R., Ahmadasas, M., Abdel-Latif, M. M., Fritschi, C., Quinn, L., Reutrakul, S., Bronas, U. G., & Çınar, A. (2024) · The AAPS Journal · doi:10.1208/s12248-024-00962-2 · Cited by 1
Efficacy of Alogliptin/Metformin Fixed-Dose Combination Tablets and Vildagliptin/Metformin Fixed-Dose Combination Tablets on Glycemic Control in Real-World Clinical Practice for the Patients with Type 2 Diabetes: A Multicenter, Open-Label, Randomized, Parallel Group, Comparative Trial
Abe, T., Takeda, Y., Sakuma, I., Okada, M., Kurigaki, A., Bessho, R., Sato, M., Kitsunai, H., Takiyama, Y., & Sakurai, M. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2024.0127 · Cited by 1
Effectiveness and safety of insulin glargine 300 U/mL in insulin‐naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis
Gourdy, P., Bonadonna, R. C., Mauricio, D., Müller‐Wieland, D., Mauquoi, C., Vera, C., Bonnemaire, M., & Freemantle, N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16008 · Cited by 1

Authors: ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., Kahan, S., Khunti, K., Leon, J., Lyons, S. K., Perry, M. L., Prahalad, P., Pratley, R. E., Seley, J. J., Stanton, R. C., & Gabbay, R. A.
ORCID: ElSayed, Nuha A.
Aleppo, Grazia
Aroda, Vanita R.
Bannuru, Raveendhara R.
Brown, Florence M.
Bruemmer, Dennis
Collins, Billy S.
Hilliard, Marisa E.
Isaacs, Diana
Johnson, Eric L.
Kahan, Scott
Khunti, Kamlesh
Lyons, Sarah K.
Perry, Mary Lou
Prahalad, Priya
Pratley, Richard E.
Seley, Jane Jeffrie
Stanton, Robert C.
Gabbay, Robert A.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2022-12-12
Volume: 46
Issue: Supplement_1
Pages: S140-S157
ISSN: 0149-5992 (ISSN-L)
DOI: 10.2337/dc23-s009
PMC: PMC9810476
OpenAlex: W4311264067
Semantic Scholar: f75bf88f7fa4c4c0cf940dad739ba96bb6d15d64
Cited by: 851
References: 114
Citations by year: 2026: 64 · 2025: 149 · 2024: 360 · 2023: 277 · 2022: 1
FWCI: 28.05
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.diabetesjournals.org/journals/pages/license (vor)
Locations: Diabetes Care (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords: glycemic control, pharmacotherapy, diabetes mellitus, antidiabetic drugs, clinical guidelines, treatment goals, quality of care
MeSH terms: Diabetes Mellitus, Endocrinology, Humans, Reference Standards, Societies, Medical, Standard of Care

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks